Quick Answer
Aquestive Therapeutics, Inc. reported Stockholders Equity of -$33.66 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed an increase of +44.0% in Stockholders Equity from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$22.40 million | Q2 2018: -$38.95 million | Q3 2018: $23.44 million | Q1 2019: -$6.06 million | Q2 2019: -$24.66 million | Q3 2019: -$34.46 million | Q1 2020: -$20.83 million | Q2 2020: -$21.39 million | Q3 2020: -$36.52 million | Q1 2021: -$51.80 million | Q2 2021: -$53.77 million | Q3 2021: -$60.35 million | Q1 2022: -$93.14 million | Q2 2022: -$96.36 million | Q3 2022: -$107.82 million | Q1 2023: -$109.24 million | Q2 2023: -$106.65 million | Q3 2023: -$102.93 million | Q1 2024: -$36.30 million | Q2 2024: -$35.48 million | Q3 2024: -$45.42 million | Q1 2025: -$60.93 million | Q2 2025: -$72.59 million | Q3 2025: -$4.11 million.
- Over the full 10 years of available data (2016 to 2025), Aquestive Therapeutics, Inc.'s Stockholders Equity has grown by 41.1%.
- Historical annual values: Fiscal year 2025: -$33.66 million | Fiscal year 2024: -$60.16 million | Fiscal year 2023: -$106.49 million | Fiscal year 2022: -$118.55 million | Fiscal year 2021: -$82.13 million | Fiscal year 2020: -$48.50 million | Fiscal year 2019: -$6.12 million | Fiscal year 2018: $10.08 million | Fiscal year 2017: -$26.50 million | Fiscal year 2016: -$57.20 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: